세계의 클로닝 및 돌연변이유발 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 유전자 유형별, 제품 유형별, 기술별, 용도별, 최종 사용자별, 지역별 경쟁(2020-2030년)

The Global Cloning & Mutagenesis Market was valued at USD 2.67 billion in 2024 and is anticipated to reach USD 7.58 billion by 2030, growing at a CAGR of 18.99%. This market is witnessing rapid growth, largely fueled by expanding applications of cloning techniques in fields such as genetic and reproductive research. The increasing number of product launches involving cloning and mutagenesis kits, along with rising governmental investment in stem cell research for therapeutic development, is further driving demand. Additionally, the global rise in the aging population-more susceptible to chronic illnesses and metabolic disorders-is expected to significantly contribute to market expansion. Heightened awareness of gene therapy benefits and early diagnostic tools, combined with increased healthcare spending on chronic disease management, also supports the market's growth trajectory. Moreover, the global burden of diseases like head and neck cancer continues to drive demand for genetic engineering tools for advanced treatment solutions.

Key Market Drivers

Rising Demand for Genetically Engineered Products in Biotechnology and Pharmaceuticals

The global demand for genetically engineered products is one of the major growth catalysts for the cloning and mutagenesis market. These technologies are vital in developing new drugs, gene therapies, vaccines, and synthetic biological products. Cloning and mutagenesis techniques allow scientists to manipulate genes for desired traits, making them indispensable in genetic research and biopharmaceutical manufacturing. Significant public investments reinforce this trend-for instance, the U.S. Department of Health and Human Services allocated over $2.5 billion to BARDA in 2023 to support advanced vaccine and therapeutic development, much of which relies on gene manipulation techniques. Similarly, under its Horizon Europe framework, the European Commission has earmarked over €1 billion for health innovation, focusing on gene-based solutions and personalized medicine.

Key Market Challenges

Ethical and Regulatory Concerns Around Genetic Manipulation

The ethical and regulatory landscape surrounding genetic engineering poses a major challenge for the cloning and mutagenesis market. Concerns about biosafety, environmental impact, and moral implications, especially in human applications like germline editing and embryonic cloning, have led to global scrutiny. While somatic cell gene editing is generally accepted, public and institutional opposition to germline modifications persists. Following incidents like the unauthorized editing of human embryos in 2018, regulatory bodies such as the WHO and UNESCO have called for stricter oversight. Regulatory inconsistencies between regions further complicate the market-while agencies like the FDA and EMA allow controlled gene therapy, other countries enforce bans on certain genetic techniques. The EU, for example, imposes rigorous regulations on GMOs, often delaying their approval. These regulatory and ethical hurdles not only slow innovation but also increase compliance costs, especially for companies operating in sensitive sectors like human therapeutics and agricultural biotechnology.

Key Market Trends

Integration of Artificial Intelligence in Genetic Engineering Workflows

The adoption of artificial intelligence in genetic research is a transformative trend in the cloning and mutagenesis market. AI and machine learning technologies are being increasingly utilized to automate gene synthesis, select optimal mutagenesis sites, design primers, and predict protein behavior after mutation. These tools help researchers conduct high-precision experiments more efficiently and cost-effectively. AI-driven analysis of large genomic datasets enables faster identification of gene targets and potential phenotypic outcomes, streamlining drug development and genetic research. Government support is also fostering this integration. For instance, the U.S. has prioritized AI in healthcare through the National Artificial Intelligence Initiative Act and allocated over $1.5 billion for related research in 2023. Similarly, Europe's Horizon Europe program promotes AI-based innovation in biotechnology. As AI systems become more advanced and widely adopted, their impact on genetic engineering is expected to enhance the reproducibility, speed, and accuracy of cloning and mutagenesis experiments across the pharmaceutical, agricultural, and research sectors.

Key Market Players

• Agilent Technologies, Inc.
• Eurofins Scientific SE
• Sartorius AG
• Collecta, Inc.
• Codex DNA Inc.
• Lonza Group AG
• Charles River Laboratories International, Inc.
• TransGene Biotech Co. Ltd.
• Takara Bio, Inc.
• Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Cloning & Mutagenesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cloning & Mutagenesis Market, By Gene Type:

• Standard
• Complex

Cloning & Mutagenesis Market, By Product Type:

• Cloning Kits
• Mutagenesis Kits

Cloning & Mutagenesis Market, By Technique:

• Topo PCR Cloning
• Blunt End Cloning
• Seamless Cloning
• Site-Directed Mutagenesis

Cloning & Mutagenesis Market, By Application:

• Gene Synthesis
• Gene Expression
• Gene Therapy
• Vaccine Research
• Others

Cloning & Mutagenesis Market, By End User:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutions
• Others

Cloning & Mutagenesis Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Cloning & Mutagenesis Market.

Available Customizations:

Global Cloning & Mutagenesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cloning & Mutagenesis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Gene Type (Standard, Complex)
  • 5.2.2. By Product Type (Cloning Kits, Mutagenesis Kits)
  • 5.2.3. By Technique (Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis, Others)
  • 5.2.4. By Application (Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, Others)
  • 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Gene Type
  • 5.3.2. By Product Type
  • 5.3.3. By Technique
  • 5.3.4. By Application
  • 5.3.5. By End User
  • 5.3.6. By Region

6. North America Cloning & Mutagenesis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Gene Type
  • 6.2.2. By Product Type
  • 6.2.3. By Technique
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cloning & Mutagenesis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Gene Type
      • 6.3.1.2.2. By Product Type
      • 6.3.1.2.3. By Technique
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Cloning & Mutagenesis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Gene Type
      • 6.3.2.2.2. By Product Type
      • 6.3.2.2.3. By Technique
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Cloning & Mutagenesis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Gene Type
      • 6.3.3.2.2. By Product Type
      • 6.3.3.2.3. By Technique
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Cloning & Mutagenesis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Gene Type
  • 7.2.2. By Product Type
  • 7.2.3. By Technique
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cloning & Mutagenesis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Gene Type
      • 7.3.1.2.2. By Product Type
      • 7.3.1.2.3. By Technique
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. Germany Cloning & Mutagenesis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Gene Type
      • 7.3.2.2.2. By Product Type
      • 7.3.2.2.3. By Technique
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Cloning & Mutagenesis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Gene Type
      • 7.3.3.2.2. By Product Type
      • 7.3.3.2.3. By Technique
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Cloning & Mutagenesis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Gene Type
      • 7.3.4.2.2. By Product Type
      • 7.3.4.2.3. By Technique
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Cloning & Mutagenesis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Gene Type
      • 7.3.5.2.2. By Product Type
      • 7.3.5.2.3. By Technique
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia-Pacific Cloning & Mutagenesis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Gene Type
  • 8.2.2. By Product Type
  • 8.2.3. By Technique
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cloning & Mutagenesis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Gene Type
      • 8.3.1.2.2. By Product Type
      • 8.3.1.2.3. By Technique
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Cloning & Mutagenesis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Gene Type
      • 8.3.2.2.2. By Product Type
      • 8.3.2.2.3. By Technique
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Cloning & Mutagenesis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Gene Type
      • 8.3.3.2.2. By Product Type
      • 8.3.3.2.3. By Technique
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Cloning & Mutagenesis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Gene Type
      • 8.3.4.2.2. By Product Type
      • 8.3.4.2.3. By Technique
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Cloning & Mutagenesis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Gene Type
      • 8.3.5.2.2. By Product Type
      • 8.3.5.2.3. By Technique
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. South America Cloning & Mutagenesis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Gene Type
  • 9.2.2. By Product Type
  • 9.2.3. By Technique
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cloning & Mutagenesis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Gene Type
      • 9.3.1.2.2. By Product Type
      • 9.3.1.2.3. By Technique
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Cloning & Mutagenesis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Gene Type
      • 9.3.2.2.2. By Product Type
      • 9.3.2.2.3. By Technique
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Cloning & Mutagenesis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Gene Type
      • 9.3.3.2.2. By Product Type
      • 9.3.3.2.3. By Technique
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. Middle East and Africa Cloning & Mutagenesis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Gene Type
  • 10.2.2. By Product Type
  • 10.2.3. By Technique
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cloning & Mutagenesis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Gene Type
      • 10.3.1.2.2. By Product Type
      • 10.3.1.2.3. By Technique
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Cloning & Mutagenesis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Gene Type
      • 10.3.2.2.2. By Product Type
      • 10.3.2.2.3. By Technique
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. UAE Cloning & Mutagenesis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Gene Type
      • 10.3.3.2.2. By Product Type
      • 10.3.3.2.3. By Technique
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Cloning & Mutagenesis Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products/Services

15. Competitive Landscape

• 15.1. Agilent Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Eurofins Scientific SE
• 15.3. Sartorius AG
• 15.4. Collecta, Inc.
• 15.5. Codex DNA Inc.
• 15.6. Lonza Group AG
• 15.7. Charles River Laboratories International, Inc.
• 15.8. TransGene Biotech Co. Ltd.
• 15.9. Takara Bio, Inc.
• 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer